S. V. Ignatyev
Research Subjects
S. V. Ignatyev has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Alexey V. Lyanguzov
Kirov Research Institute of Hematology and Blood Transfusion
10 shared publications - Igor Paramonov
Federal State‐Financed Scientific Institution: Kirov Research Institute of Hematology and Blood Transfusion Under the Federal Medical Biological Agency Kirov Russia
6 shared publications - S. L. Kalinina
Kirov Research Institute of Hematology and Blood Transfusion
5 shared publications - O. M. Tselousova
Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency
3 shared publications - O. Yu. Sergunina
Kirov Research Institute of Hematology and Blood Transfusion
3 shared publications - Andrey Yu. Bulanov
N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow, Russia
2 shared publications
Latest Publications
- 31 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 6,p. 21-27
Use of the international normalized ratio for the diagnosis of sepsis in thrombocytopenic blood cancer patients
Objective. To investigate the role of international normalized ratio (INR) as a marker of sepsis-related clotting disorders in blood cancer patients with thrombocytopenia. Material and methods. A retrospective analysis included 279 patients with hematologic malignancies admitted to ICU due to infectious complications or sepsis. Clinical and laboratory data, specifically those required for calculating Sequential Organ Failure Assessment (SOFA) scores, were extracted. Predictive value of individual SOFA parameters for mortality was evaluated. We analyzed predictive role of coagulation parameters in sepsis to find the most suitable alternative to platelet count. Results. Sepsis, as defined by the Sepsis-3 criteria, was diagnosed in 256 (91.7%) out of 279 patients. The overall mortality rate was 34.7%. Thrombocytopenia (platelet count <150·109/L) was present in 236 (84.5%) of patients. In 58 (23.0%) patients, diagnosis of sepsis was due to infectious complication with acute multiple organ dysfunction (SOFA score ≥2) and thrombocytopenia <100·109/l. Comparison of survival in these patients with survival of patients with complex homeostasis disorders according to SOFA scale revealed significant differences (Logrank χ2=12.8; p=0.0003). Platelet count was not a predictor of unfavorable outcome (OR 0.996; 95% CI 0.992—1.0001; p=0.058). Multivariate analysis revealed that the most significant predictor of mortality associated with hemostasis disorders in sepsis in patients with blood diseases was INR (OR 2.14; 95% CI 1.168—3.921; p=0.014). Conclusion. Elevated INR in patients with blood diseases and thrombocytopenia preceding infectious complications and sepsis is associated with higher risk of mortality and may be used as indicator of hemostasis disorders according to SOFA score in diagnosis of sepsis.
- 31 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 6,p. 21-27
Use of the international normalized ratio for the diagnosis of sepsis in thrombocytopenic blood cancer patients
Objective. To investigate the role of international normalized ratio (INR) as a marker of sepsis-related clotting disorders in blood cancer patients with thrombocytopenia. Material and methods. A retrospective analysis included 279 patients with hematologic malignancies admitted to ICU due to infectious complications or sepsis. Clinical and laboratory data, specifically those required for calculating Sequential Organ Failure Assessment (SOFA) scores, were extracted. Predictive value of individual SOFA parameters for mortality was evaluated. We analyzed predictive role of coagulation parameters in sepsis to find the most suitable alternative to platelet count. Results. Sepsis, as defined by the Sepsis-3 criteria, was diagnosed in 256 (91.7%) out of 279 patients. The overall mortality rate was 34.7%. Thrombocytopenia (platelet count <150·109/L) was present in 236 (84.5%) of patients. In 58 (23.0%) patients, diagnosis of sepsis was due to infectious complication with acute multiple organ dysfunction (SOFA score ≥2) and thrombocytopenia <100·109/l. Comparison of survival in these patients with survival of patients with complex homeostasis disorders according to SOFA scale revealed significant differences (Logrank χ2=12.8; p=0.0003). Platelet count was not a predictor of unfavorable outcome (OR 0.996; 95% CI 0.992—1.0001; p=0.058). Multivariate analysis revealed that the most significant predictor of mortality associated with hemostasis disorders in sepsis in patients with blood diseases was INR (OR 2.14; 95% CI 1.168—3.921; p=0.014). Conclusion. Elevated INR in patients with blood diseases and thrombocytopenia preceding infectious complications and sepsis is associated with higher risk of mortality and may be used as indicator of hemostasis disorders according to SOFA score in diagnosis of sepsis.
- 22 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5,p. 74-80
Endothelial factors for prediction of mortality in blood cancer patients with sepsis
Objective. To investigate predictive capability of serum von Willebrand factor (VWF:Ag) and syndecan-1 (SDC-1) in blood cancer patients with sepsis. Material and methods. The study encompassed a cohort of 71 blood cancer patients with sepsis between 2020 and 2022. Disease severity and organ dysfunction were evaluated using the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sepsis-related Organ Failure Assessment (SOFA) scoring systems. Prognostic value of SDC-1 and VWF:Ag concentrations in predicting mortality was assessed. Results. The mortality rate was 39.4%. Comparative analysis of SDC-1 and VWF:Ag concentrations in patients with different outcomes revealed significantly higher concentrations of SDC-1 (Mann-Whitney U=217.0; p<0.001) and VWF:Ag (Mann-Whitney U=268.5; p<0.001) in dead patients. No significant differences were observed in procalcitonin and C-reactive protein (CRP) concentrations between survivors and non-survivors. Positive correlations were demonstrated between SDC-1 concentrations and SOFA scores (Spearman’s rho=0.338, p=0.004), as well as APACHE II scores (Spearman’s rho=0.346; p=0.003). Similarly, positive correlations were observed between VWF:Ag concentrations and APACHE II scores (Spearman’s rho=0.296; p=0.012), as well as APACHE II scores (Spearman’s rho=0.272, p=0.022). Survival analysis revealed significant differences in outcomes between patients with SDC-1 concentrations greater and less than the median (14 ng/ml) (log-rank χ2=5.77, p=0.016) and VWF:Ag concentrations greater and less than the median (383%) (log-rank χ2=11.74; p=0.0006). Multivariate analysis demonstrated a significant association between SDC-1 (OR=1.052; 95% CI 1.020—1.084; p=0.001) and VWF:Ag (OR=1.005; 95% CI 1.001—1.009; p=0.011) concentrations with mortality. Conclusion. SDC-1 and VWF:Ag concentrations may be potential biomarkers for predicting mortality in blood cancer patients with sepsis.
- 22 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5,p. 74-80
Endothelial factors for prediction of mortality in blood cancer patients with sepsis
Objective. To investigate predictive capability of serum von Willebrand factor (VWF:Ag) and syndecan-1 (SDC-1) in blood cancer patients with sepsis. Material and methods. The study encompassed a cohort of 71 blood cancer patients with sepsis between 2020 and 2022. Disease severity and organ dysfunction were evaluated using the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sepsis-related Organ Failure Assessment (SOFA) scoring systems. Prognostic value of SDC-1 and VWF:Ag concentrations in predicting mortality was assessed. Results. The mortality rate was 39.4%. Comparative analysis of SDC-1 and VWF:Ag concentrations in patients with different outcomes revealed significantly higher concentrations of SDC-1 (Mann-Whitney U=217.0; p<0.001) and VWF:Ag (Mann-Whitney U=268.5; p<0.001) in dead patients. No significant differences were observed in procalcitonin and C-reactive protein (CRP) concentrations between survivors and non-survivors. Positive correlations were demonstrated between SDC-1 concentrations and SOFA scores (Spearman’s rho=0.338, p=0.004), as well as APACHE II scores (Spearman’s rho=0.346; p=0.003). Similarly, positive correlations were observed between VWF:Ag concentrations and APACHE II scores (Spearman’s rho=0.296; p=0.012), as well as APACHE II scores (Spearman’s rho=0.272, p=0.022). Survival analysis revealed significant differences in outcomes between patients with SDC-1 concentrations greater and less than the median (14 ng/ml) (log-rank χ2=5.77, p=0.016) and VWF:Ag concentrations greater and less than the median (383%) (log-rank χ2=11.74; p=0.0006). Multivariate analysis demonstrated a significant association between SDC-1 (OR=1.052; 95% CI 1.020—1.084; p=0.001) and VWF:Ag (OR=1.005; 95% CI 1.001—1.009; p=0.011) concentrations with mortality. Conclusion. SDC-1 and VWF:Ag concentrations may be potential biomarkers for predicting mortality in blood cancer patients with sepsis.
- Open Access
- 20 August 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
Freeze-dried plasma for emergency transfusion care in extreme conditions
Лиофилизированная плазма для оказания экстренной трансфузиологической помощи в экстремальных условиях
- 20 August 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
Open AccessFreeze-dried plasma for emergency transfusion care in extreme conditions
Лиофилизированная плазма для оказания экстренной трансфузиологической помощи в экстремальных условиях
- Open Access
- 30 October 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (3) , 66-70
Hageman’s disease (hereditary factor XII deficiency). Review of literature, clinical observations
Hageman’s disease is a rare hereditary disorder of hemostasis, characterized by a deficiency of coagulation factor XII, accompanied by prolongation of blood clotting time (Lee–White) and activated partial thromboplastin time. These laboratory abnormalities are often thought to indicate an increased risk of bleeding, similar to hemophilia. This leads to the unnecessary use of transfusions and hemostatic therapy, since bleeding is rare in these patients. The article provides a review of the literature on Hageman’s disease and describes clinical cases of surgical treatment of children with factor XII deficiency.
- 30 October 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (3) , 66-70
Open AccessHageman’s disease (hereditary factor XII deficiency). Review of literature, clinical observations
Hageman’s disease is a rare hereditary disorder of hemostasis, characterized by a deficiency of coagulation factor XII, accompanied by prolongation of blood clotting time (Lee–White) and activated partial thromboplastin time. These laboratory abnormalities are often thought to indicate an increased risk of bleeding, similar to hemophilia. This leads to the unnecessary use of transfusions and hemostatic therapy, since bleeding is rare in these patients. The article provides a review of the literature on Hageman’s disease and describes clinical cases of surgical treatment of children with factor XII deficiency.
- Open Access
- 3 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 243-250
Thrombodynamics test efficacy in predicting thromboembolic complications in patients with lymphoproliferative disorders
Background. Patients with lymphoproliferative disorders (LPD) are at increased risk of developing venous thromboembolic complications (VTEC). Existing risk assessment systems for VTEC (Khorana, Vienna, ThroLy, etc.) do not have sufficient prognostic accuracy in this patient population. The thrombodynamics test may improve the prognosis of VTEC and optimize the prophylactic use of anticoagulants in these patients.Aim. To evaluate thrombodynamics test efficacy in assessing the risk of venous VTEC in LPD patients.Materials and methods. Medical data of 990 patients with LPD who received treatment at the Kirov Research Institute of Hematology and Blood Transfusion from 2019 to 2021 were analyzed. Coagulation parameters were evaluated at admission, as well as the risk of developing VTEC by prognostic scales Khorana, Vienna, ThroLy, SAVED, and Padua. Data are presented as median and interquartile range. Mann–Whitney U test was used to compare two independent groups. Correlation was determined using Spearman’s rank correlation. Logistic regression was used to determine dependencies. The diagnostic value of laboratory tests was established through ROC analysis.Results. In the overall cohort of LPD patients, the incidence of VTEC was 2.1 %. Screening coagulogram parameters in these patients did not exceed reference values. Patients with LPD who developed VTEC initially showed a significant increase in clot velocity (V), initial growth velocity (Vi), and clot size (Cs). It was found that the presence of spontaneous clots significantly increased the chances of developing a thrombotic event (odds ratio 3.99; 95 % confidence interval 1.56–10.22; p = 0.004). It was also determined that V velocity is an independent predictor of VTEC (adjusted odds ratio 1.053; 95 % confidence interval 1.016–1.090; p = 0.0046). The AUC determined by ROC analysis for the V parameter was 0.722 (threshold value 30.7 μm/min sensitivity 81 %, specificity 57.4 %).Conclusion. Clot growth velocity is the most informative parameter of thrombodynamics test in predicting VTEC.
- 3 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 243-250
Open AccessThrombodynamics test efficacy in predicting thromboembolic complications in patients with lymphoproliferative disorders
Background. Patients with lymphoproliferative disorders (LPD) are at increased risk of developing venous thromboembolic complications (VTEC). Existing risk assessment systems for VTEC (Khorana, Vienna, ThroLy, etc.) do not have sufficient prognostic accuracy in this patient population. The thrombodynamics test may improve the prognosis of VTEC and optimize the prophylactic use of anticoagulants in these patients.Aim. To evaluate thrombodynamics test efficacy in assessing the risk of venous VTEC in LPD patients.Materials and methods. Medical data of 990 patients with LPD who received treatment at the Kirov Research Institute of Hematology and Blood Transfusion from 2019 to 2021 were analyzed. Coagulation parameters were evaluated at admission, as well as the risk of developing VTEC by prognostic scales Khorana, Vienna, ThroLy, SAVED, and Padua. Data are presented as median and interquartile range. Mann–Whitney U test was used to compare two independent groups. Correlation was determined using Spearman’s rank correlation. Logistic regression was used to determine dependencies. The diagnostic value of laboratory tests was established through ROC analysis.Results. In the overall cohort of LPD patients, the incidence of VTEC was 2.1 %. Screening coagulogram parameters in these patients did not exceed reference values. Patients with LPD who developed VTEC initially showed a significant increase in clot velocity (V), initial growth velocity (Vi), and clot size (Cs). It was found that the presence of spontaneous clots significantly increased the chances of developing a thrombotic event (odds ratio 3.99; 95 % confidence interval 1.56–10.22; p = 0.004). It was also determined that V velocity is an independent predictor of VTEC (adjusted odds ratio 1.053; 95 % confidence interval 1.016–1.090; p = 0.0046). The AUC determined by ROC analysis for the V parameter was 0.722 (threshold value 30.7 μm/min sensitivity 81 %, specificity 57.4 %).Conclusion. Clot growth velocity is the most informative parameter of thrombodynamics test in predicting VTEC.
- Open Access
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 96-101
The use of emicizumab in children with hemophilia A without inhibitors in the real-world clinical setting
In our country, the use of emicizumab in children with hemophilia A without inhibitors (HA) in the real-world clinical setting is limited and is available only as few individual case reports. Our aim was to evaluate the effectiveness and safety of the prophylactic use of emicizumab in children with severe HA in the real-world clinical setting. We conducted a retrospective analysis of medical records of children with HA who had received emicizumab at 9 centers based in the Russian Federation. We assessed the annualized bleeding rate (ABR), annualized spontaneous bleeding rate (ASBR), annualized joint bleeding rate (AJBR), annualized bleeding rate for bleeding episodes that required additional treatment with FVIII concentrate (ABRRT) and the number of hospital admissions for bleeding both before and after the treatment with emicizumab, as well as the occurrence and severity of adverse events during the therapy. Ethics committee approval was not required for this study because it involved the use of aggregated retrospective data from routine clinical practice that were fully anonymized. Two emicizumab administration regimens were compared with regard to their effectiveness. Before the treatment with emicizumab, ABR was 5.38 (95% confidence interval (CI) 3.90–7.64), ASBR – 4.16 (95% CI 2.99–5.94), AJBR – 2.7 (95% CI 1.87–4.03), and ABRRT – 4.8 (95% CI 3.37–7.08). After the initiation of the treatment with emicizumab, the bleeding rate plummeted: ABR decreased by 93.9% (95% CI 88.8–96.7), ASBR – by 96.9% (95% CI 93.1–98.6), AJBR – by 96.1% (95% CI 90.4–98.4%) and ABRRT – by 95.1% (95% CI 90.0–97.6). During the treatment with emicizumab, the rate of bleeding episodes that required hospital admission decreased from 1.58 (95% CI 0.98–2.68) to 0.04 (0.01–0.10), which amounted to 97.6% (95% CI 91.1–99.4). The median follow-up time for the patients treated with emicizumab was 15.5 months (range 9–29 months). When comparing the annualized bleeding rates in the groups of the patients who were preventively treated with emicizumab at doses of 3 mg/kg (administered once every 2 weeks) and 1.5 mg/kg (once per week), we didn't find any statistically significant differences. In the real-world clinical setting, the use of emicizumab in the children with HA led to a significant reduction in all bleeding episodes (by more than 90%), regardless of the administration regimen.
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 96-101
Open AccessThe use of emicizumab in children with hemophilia A without inhibitors in the real-world clinical setting
In our country, the use of emicizumab in children with hemophilia A without inhibitors (HA) in the real-world clinical setting is limited and is available only as few individual case reports. Our aim was to evaluate the effectiveness and safety of the prophylactic use of emicizumab in children with severe HA in the real-world clinical setting. We conducted a retrospective analysis of medical records of children with HA who had received emicizumab at 9 centers based in the Russian Federation. We assessed the annualized bleeding rate (ABR), annualized spontaneous bleeding rate (ASBR), annualized joint bleeding rate (AJBR), annualized bleeding rate for bleeding episodes that required additional treatment with FVIII concentrate (ABRRT) and the number of hospital admissions for bleeding both before and after the treatment with emicizumab, as well as the occurrence and severity of adverse events during the therapy. Ethics committee approval was not required for this study because it involved the use of aggregated retrospective data from routine clinical practice that were fully anonymized. Two emicizumab administration regimens were compared with regard to their effectiveness. Before the treatment with emicizumab, ABR was 5.38 (95% confidence interval (CI) 3.90–7.64), ASBR – 4.16 (95% CI 2.99–5.94), AJBR – 2.7 (95% CI 1.87–4.03), and ABRRT – 4.8 (95% CI 3.37–7.08). After the initiation of the treatment with emicizumab, the bleeding rate plummeted: ABR decreased by 93.9% (95% CI 88.8–96.7), ASBR – by 96.9% (95% CI 93.1–98.6), AJBR – by 96.1% (95% CI 90.4–98.4%) and ABRRT – by 95.1% (95% CI 90.0–97.6). During the treatment with emicizumab, the rate of bleeding episodes that required hospital admission decreased from 1.58 (95% CI 0.98–2.68) to 0.04 (0.01–0.10), which amounted to 97.6% (95% CI 91.1–99.4). The median follow-up time for the patients treated with emicizumab was 15.5 months (range 9–29 months). When comparing the annualized bleeding rates in the groups of the patients who were preventively treated with emicizumab at doses of 3 mg/kg (administered once every 2 weeks) and 1.5 mg/kg (once per week), we didn't find any statistically significant differences. In the real-world clinical setting, the use of emicizumab in the children with HA led to a significant reduction in all bleeding episodes (by more than 90%), regardless of the administration regimen.
- 9 February 2023
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 1
Predictors of ICU mortality in patients with hemoblastosis and infectious complications
Objective. To identify predictors of ICU mortality in patients with hemoblastosis and infectious complications. Material and methods. The study included 202 ICU patients with hemoblastosis and infectious complications between 2018 and 2021. We evaluated SIRS, qSOFA and SOFA scores, as well as other potential significant predictors. Binomial multiple logistic regression approach was used to create prognostic model. Results. Mortality rate was 33% (67 out of 202), odds ratio — 0.49 (67 to 136). The median of the follow-up period was 6 (3-14) days. Univariate analysis revealed tachypnea, hypoxemia, hemodynamic instability (blood pressure decrease, need for vasopressor support), liver damage (hyperbilirubinemia, hypoproteinemia, hypoalbuminemia) and impaired consciousness as predictors of ICU mortality. Multivariate analysis revealed 3 significant predictors of mortality: impaired consciousness, platelet count and serum protein. Model quality was evaluated on a test set with a threshold of high probability of death ≥32%. Accuracy was 0.816 (95% CI 0.679-0.912), sensitivity — 0.80, specificity — 0.82. Conclusion. Impaired consciousness, decreased platelet count and serum protein are the most important predictors of mortality in ICU patients with hemoblastosis and infectious complications. These data can be used in clinical practice.
- 9 February 2023
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 1
Predictors of ICU mortality in patients with hemoblastosis and infectious complications
Objective. To identify predictors of ICU mortality in patients with hemoblastosis and infectious complications. Material and methods. The study included 202 ICU patients with hemoblastosis and infectious complications between 2018 and 2021. We evaluated SIRS, qSOFA and SOFA scores, as well as other potential significant predictors. Binomial multiple logistic regression approach was used to create prognostic model. Results. Mortality rate was 33% (67 out of 202), odds ratio — 0.49 (67 to 136). The median of the follow-up period was 6 (3-14) days. Univariate analysis revealed tachypnea, hypoxemia, hemodynamic instability (blood pressure decrease, need for vasopressor support), liver damage (hyperbilirubinemia, hypoproteinemia, hypoalbuminemia) and impaired consciousness as predictors of ICU mortality. Multivariate analysis revealed 3 significant predictors of mortality: impaired consciousness, platelet count and serum protein. Model quality was evaluated on a test set with a threshold of high probability of death ≥32%. Accuracy was 0.816 (95% CI 0.679-0.912), sensitivity — 0.80, specificity — 0.82. Conclusion. Impaired consciousness, decreased platelet count and serum protein are the most important predictors of mortality in ICU patients with hemoblastosis and infectious complications. These data can be used in clinical practice.
- Open Access
- 9 November 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (3) , 107-112-112
Atipical course of clostridial colitis in child with Hodgkin’s lymphoma
The wide antibiotics use in different areas of medicine has significantly increased the incidence of pseudomembranous colitis caused by Clostridium difficile. Strong necessity of antibacterial therapy in hematological patients is the reason of a higher frequency of this complication after programmed chemotherapy and hematopoietic stem cell transplantation. The atypical course of clostridial colitis makes it difficult to diagnose, leads to delay of treatment and fatal complications. We presented the case of clostridial colitis with atypical clinical manifestations in the 8-year-old child with Hodgkin’s lymphoma. Disease was complicated by colon perforation and fecal peritonitis, which required surgery and long-term rehabilitation. The analysis of publications devoted to clostridial colitis in patients with hematological malignancies was carried out and possible reasons of its atypical course was reviewed. The ways to improve the diagnosis, treatment and prevention of this serious complication are presented.
- 9 November 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (3) , 107-112-112
Open AccessAtipical course of clostridial colitis in child with Hodgkin’s lymphoma
The wide antibiotics use in different areas of medicine has significantly increased the incidence of pseudomembranous colitis caused by Clostridium difficile. Strong necessity of antibacterial therapy in hematological patients is the reason of a higher frequency of this complication after programmed chemotherapy and hematopoietic stem cell transplantation. The atypical course of clostridial colitis makes it difficult to diagnose, leads to delay of treatment and fatal complications. We presented the case of clostridial colitis with atypical clinical manifestations in the 8-year-old child with Hodgkin’s lymphoma. Disease was complicated by colon perforation and fecal peritonitis, which required surgery and long-term rehabilitation. The analysis of publications devoted to clostridial colitis in patients with hematological malignancies was carried out and possible reasons of its atypical course was reviewed. The ways to improve the diagnosis, treatment and prevention of this serious complication are presented.
- Open Access
- 14 April 2022
- Published by Publishing House ABV Press in Oncohematology
- Vol. 17 (2) , 134-140
Issue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases
The incidence of malignant lymphomas has been increasing in recent years worldwide. These diseases are often accompanied by venous thromboembolic complications (VTEC). The development of VTEC leads to interrupting of therapy, increasing mortality and significant rising of treatment costs. Anticoagulants are effective in VTEC prophylaxis. Prescribing of anticoagulant therapy is based on VTEC different risk scales, which are far from perfect. The search of additional features for hemostasis assessment can increase the prognostic value of these scales. The optimization of VTEC risk scales can improve efficacy of anticoagulant therapy and decrease an incidence of thrombotic events in patient with malignant lymphomas. The article presents a literature review and own clinical observations regarding the VTEC risk assessment in patients with lymphoproliferative diseases.
- 14 April 2022
- Published by Publishing House ABV Press in Oncohematology
- Vol. 17 (2) , 134-140
Open AccessIssue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases
The incidence of malignant lymphomas has been increasing in recent years worldwide. These diseases are often accompanied by venous thromboembolic complications (VTEC). The development of VTEC leads to interrupting of therapy, increasing mortality and significant rising of treatment costs. Anticoagulants are effective in VTEC prophylaxis. Prescribing of anticoagulant therapy is based on VTEC different risk scales, which are far from perfect. The search of additional features for hemostasis assessment can increase the prognostic value of these scales. The optimization of VTEC risk scales can improve efficacy of anticoagulant therapy and decrease an incidence of thrombotic events in patient with malignant lymphomas. The article presents a literature review and own clinical observations regarding the VTEC risk assessment in patients with lymphoproliferative diseases.
- 24 December 2020
- Published by Vitebsk State Medical University in Novosti Khirurgii
- Vol. 28 (6) , 664-670
Coagulation Disorders in Children with Destructive Forms of Appendicitis
Цель. Оценить состояние коагуляционного звена гемостаза у детей с деструктивными формами аппендицита в раннем послеоперационном периоде. Материал и методы. В исследование были включены 30 детей с деструктивными формами острого аппендицита в возрасте 7-14 лет. Группу контроля составили 50 здоровых детей. Выраженность интоксикационно-воспалительного синдрома оценивали по данным гемограммы, лейкоцитарного индекса интоксикации и биохимического анализа крови, состояние коагуляционного звена гемостаза – на основании скрининговых, локальных тестов и интегрального теста «Тромбодинамика». Результаты. Отмечено значимое увеличение количества лейкоцитов, палочкоядерных и сегменто-ядерных нейтрофилов, СОЭ у пациентов детского возраста с деструктивными формами острого аппендицита в раннем послеоперационном периоде. Лейкоцитарный индекс интоксикации соответствовал средней и тяжелой степени тяжести пациентов – 5,73; 3,6-7,4 (Ме; Q1-Q3), С-реактивный белок в исследуемой группе превышал норму в 32 раза – 163,8; 132,8-224,9 мг/л (Ме; Q1-Q3). Выявлено статистически достоверное увеличение концентрации фибриногена (5,9±1,0 г/л), растворимых фибринмономерных комплексов (204,0±59,1 мкг/мл), фактора VIII (301,3±96,6%), фактора фон Виллебранда (226,0±62,5%) и его активности (161,5±36,2%), значимое повышение показателей интегрального теста «Тромбодинамика» – начальной скорости роста сгустка Vi (60,5±3,9 мкм/мин), стационарной скорости роста сгустка Vst (41,1±3,9 мкм/мин), размера сгустка CS (1444,2±192,9 мкм) и плотности сгустка D (31157,6±2599,3 у.е.). Кроме того, у всех пациентов исследуемой группы установлено угнетение фибринолитической активности плазмы. Заключение. Деструктивные формы аппендицита сопровождаются выраженным интоксикационно-воспалительным синдромом в сочетании с гиперкоагуляционными нарушениями системы гемостаза, что обуславливает состояние повышенной тромботической готовности, которое при наличии дополнительных факторов может реализоваться в тромбоз. Это является основанием для дополнительных исследований и более тщательного диагностического поиска тромбоэмболических осложнений у детей. Научная новизна статьи Впервые изучены маркеры гиперкоагуляционных состояний и повреждения сосудистого эндотелия (фактора VIII, фактора фон Виллебранда, теста «Тромбодинамика») у детей с деструктивными формами аппендицита в раннем послеоперационном периоде. Впервые доказано наличие протромботической готовности у пациентов данной категории.
- 24 December 2020
- Published by Vitebsk State Medical University in Novosti Khirurgii
- Vol. 28 (6) , 664-670
Coagulation Disorders in Children with Destructive Forms of Appendicitis
Цель. Оценить состояние коагуляционного звена гемостаза у детей с деструктивными формами аппендицита в раннем послеоперационном периоде. Материал и методы. В исследование были включены 30 детей с деструктивными формами острого аппендицита в возрасте 7-14 лет. Группу контроля составили 50 здоровых детей. Выраженность интоксикационно-воспалительного синдрома оценивали по данным гемограммы, лейкоцитарного индекса интоксикации и биохимического анализа крови, состояние коагуляционного звена гемостаза – на основании скрининговых, локальных тестов и интегрального теста «Тромбодинамика». Результаты. Отмечено значимое увеличение количества лейкоцитов, палочкоядерных и сегменто-ядерных нейтрофилов, СОЭ у пациентов детского возраста с деструктивными формами острого аппендицита в раннем послеоперационном периоде. Лейкоцитарный индекс интоксикации соответствовал средней и тяжелой степени тяжести пациентов – 5,73; 3,6-7,4 (Ме; Q1-Q3), С-реактивный белок в исследуемой группе превышал норму в 32 раза – 163,8; 132,8-224,9 мг/л (Ме; Q1-Q3). Выявлено статистически достоверное увеличение концентрации фибриногена (5,9±1,0 г/л), растворимых фибринмономерных комплексов (204,0±59,1 мкг/мл), фактора VIII (301,3±96,6%), фактора фон Виллебранда (226,0±62,5%) и его активности (161,5±36,2%), значимое повышение показателей интегрального теста «Тромбодинамика» – начальной скорости роста сгустка Vi (60,5±3,9 мкм/мин), стационарной скорости роста сгустка Vst (41,1±3,9 мкм/мин), размера сгустка CS (1444,2±192,9 мкм) и плотности сгустка D (31157,6±2599,3 у.е.). Кроме того, у всех пациентов исследуемой группы установлено угнетение фибринолитической активности плазмы. Заключение. Деструктивные формы аппендицита сопровождаются выраженным интоксикационно-воспалительным синдромом в сочетании с гиперкоагуляционными нарушениями системы гемостаза, что обуславливает состояние повышенной тромботической готовности, которое при наличии дополнительных факторов может реализоваться в тромбоз. Это является основанием для дополнительных исследований и более тщательного диагностического поиска тромбоэмболических осложнений у детей. Научная новизна статьи Впервые изучены маркеры гиперкоагуляционных состояний и повреждения сосудистого эндотелия (фактора VIII, фактора фон Виллебранда, теста «Тромбодинамика») у детей с деструктивными формами аппендицита в раннем послеоперационном периоде. Впервые доказано наличие протромботической готовности у пациентов данной категории.